The evolution of Pseudomonas aeruginosa during antibiotic rotation in a medical intensive care unit: the RADAR-trial

International Journal of Antimicrobial Agents
D T TsukayamaRADAR trial

Abstract

Bacterial spread between patients may contribute to the high prevalence of antibiotic-resistant pathogens within ICUs. The aim of this study was to evaluate the fate of Pseudomonas aeruginosa during the different antibiotic regimens. Susceptibility patterns and genotyping were performed to determine whether there was a predominant clone and to track the spread of resistant strains within the unit. Twenty-eight different ribotypes were found among 82 Pseudomonas isolates. Four ribotypes accounted for 42 (51%) isolates and were designated the "major clones" occurring throughout multiple cycles. The ribotypes with multiple occurrences were more resistant to antibiotics than ribotypes that appeared only once. The correlation of antibiotic use with antibiotic resistance and the finding of a large number of ribotypes suggested that de novo development of antibiotic resistance is a likely event in P. aeruginosa. In addition, ribotypes associated with antibiotic resistance appeared to have a survival advantage and can become frequent colonizers in the ICU.

Citations

Jun 30, 2005·Current Opinion in Infectious Diseases·Shiri Navon-VeneziaYehuda Carmeli
Mar 13, 2015·Iranian Red Crescent Medical Journal·Nastaran Fazeli, Hassan Momtaz
Oct 3, 2006·Expert Review of Anti-infective Therapy·Paolo Grossi, Daniela Dalla Gasperina
Mar 29, 2011·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Johan W MoutonJohn Turnidge
Aug 5, 2010·Critical Care Medicine·Tejal N GandhiLaraine L Washer
Jan 30, 2008·Pharmacotherapy·Anthony M NicasioDavid P Nicolau
Dec 24, 2010·Annals of the New York Academy of Sciences·A M BalI M Gould
Sep 1, 2006·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Nozha BrahmiMouldi Amamou
Mar 31, 2015·Future Microbiology·Nienke L PlantingaMarc J M Bonten
May 22, 2020·European Journal of Medical Research·Mina Pourmbarak Mahnaie, Hassan Mahmoudi
Aug 20, 2021·British Journal of Clinical Pharmacology·Marianneta Chatzopoulou, Lucy Reynolds

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.